Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | TPO | P07202 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE6D | O43924 | 1/20 | 0.37 |
| ▸ | PDE8A | O60658 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232090 | 0.73 | PNP (0.37) | PDE4APDE4BPDE4CPDE4DPDE3A | |
| SCHEMBL8148624 | 0.73 | ADORA2B (0.50) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL5229210 | 0.70 | ADORA2B (0.50) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL6231520 | 0.70 | ADORA2A (0.46) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Hydrochloric Acid SCHEMBL5231288 | 0.69 | ADORA2B (0.49) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3420036 | 0.69 | PDE3B (0.36) | PDE4APDE4BPDE4CPDE4DPDE3A | |
| SCHEMBL14060874 | 0.68 | PDE2A (0.36) | PDE4APDE4BPDE4CPDE4DPDE3A | |
| SCHEMBL864455 | 0.67 | ADORA2A (0.58) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL18112639 | 0.67 | ADORA2A (0.58) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| 3-Methylxanthine SCHEMBL237146 | 0.67 | ADORA2A (0.64) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997691-B | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2023-11-07 | — | — | CN | claimed |
| EP-2434895-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2012-04-04 | — | — | EP | claimed |
| WO-2010132127-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-11-18 | — | — | WO | claimed |
| EP-1624893-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2006-02-15 | — | — | EP | claimed |
| US-20040259792-A1 | Inhibitors of phosphodiesterases in infertility | LABORATOIRES SERONO SA (CH) | 2004-12-23 | — | — | US | claimed |
| WO-2004087211-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-10-14 | — | — | WO | claimed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | claimed |
| JP-H08507068-A | — | — | 1996-07-30 | — | — | JP | claimed |
| EP-0686157-A1 | 2-BENZYL-POLYCYCLIC GUANINE DERIVATIVES AND PROCESS FOR PREPARING THEM | SCHERING CORPORATION (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1994019351-A1 | 2-BENZYL-POLYCYCLIC GUANINE DERIVATIVES AND PROCESS FOR PREPARING THEM | SCHERING CORPORATION (US) | 1994-09-01 | — | — | WO | claimed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | claimed |
| EP-4655411-A2 | ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDE PROBES | DNA Script (FR) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024156896-A2 | ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDE PROBES | DNA SCRIPT (FR) | 2024-08-02 | — | — | WO | disclosed |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | disclosed |
| US-11866779-B2 | Jettison-MS for nucleic acid species | NORTHEASTERN UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20040259792-A1 | Inhibitors of phosphodiesterases in infertility | LABORATOIRES SERONO SA (CH) | 2004-12-23 | — | — | US | disclosed |
| WO-2004087211-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-10-14 | — | — | WO | disclosed |
| WO-2003047588-A1 | KIT FOR REDUCING ACHING CAUSED BY PDE-V INHIBITORS | PFIZER LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| WO-1999059584-A1 | COMBINATION OF PHENTOLAMINE AND CYCLIC GMP PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | SCHERING CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0423805-A2 | Condensed purine derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259792-A1 | Inhibitors of phosphodiesterases in infertility | PDE5A, PDE2A, PDE3A | PDE4A 6/4885PDE4B 8/4885PDE4C 7/4885 |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA1, ADORA2B | PDE4A 128/4885PDE4B 125/4885PDE4C 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.